BigHat Biosciences, which uses AI to design better antibodies, raises $19M Series A led by Andreessen Horowitz, bringing its total raised to $25M
Kyle Wiggers / VentureBeat :
Context & Ripple Effects
BigHat Biosciences' $19M Series A lands in the middle of an early-2021 funding wave for AI-first drug discovery: weeks earlier BenchSci raised a $22M Series B to cut drug-discovery research costs, and two days after this round Immunai pulled in a $60M Series A to map the immune system with machine learning.
The strategic detail is the lead investor: Andreessen Horowitz is planting a flag in computational biology it would keep watering, most visibly with Formation Bio's $372M Series D three years later — making BigHat one of the firm's earliest data points that software methods could be applied to therapeutic design.
First-order effects
- BigHat gets the capital to scale its AI-driven antibody design platform from proof-of-concept toward preclinical candidates, with a16z's backing signaling access to follow-on capital beyond the $25M total raised.
Second-order effects
- Rivals in adjacent AI-drug-discovery niches — Immunai in immunology data, Anagenex in large-scale dataset generation — raise rounds two to three times BigHat's size within months, pushing up the price of ML talent and proprietary biological datasets across the category.
Third-order effects
- If the trajectory holds — from ~$20M Series As in 2021 to Formation Bio's $600M+ total by 2024 — AI-native biotech consolidates into heavily capitalized platforms competing for pharma co-development deals, squeezing out underfunded entrants.
The trend: AI-driven drug discovery is scaling from boutique Series A experiments into mega-funded platform companies, with generalist firms like Andreessen Horowitz replacing traditional biotech VCs as the anchor backers.